CD123 (IL-3RA)
Assets acting on this target.
- Class
- Anti-CD123 antibody-drug conjugate (KSP inhibitor payload)
Assets acting on this target.
1 of 1 assets (1 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| VIP943 | Vincerx Pharma | CD123 (IL-3RA) | Acute Myeloid Leukemia | Ph 1 | Vincerx Pharma is winding down: its board approved a plan of liquidation and dissolution (announced 2025-04-17) and its Nasdaq trading was suspended on 2025-04-23. | source ↗ |